5.94 USD
▲+0.23+6.45%
盘后 5.50 -1.43%
2026-08-03
市值
$213.94M
市盈率
—
EPS
-1.11
股息率
—
52 周区间
1.00 – 6.91
成交量
368.37K
Beta
-0.99
目标价
9.00
52W 低 1.0052W 高 6.91
价格走势
公司简介
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ...